GHRH vs GHRP: Sermorelin, Tesamorelin and Ipamorelin Compared
GHRH and GHRP peptides compared: Sermorelin, Tesamorelin, Ipamorelin and CJC-1295. Mechanisms of action, differences and research overview.
The growth hormone axis (GH axis) is among the better-studied endocrine systems. Recombinant growth hormone (HGH) was a central approach in clinical research for decades, but it carries drawbacks: supraphysiological, non-pulsatile GH levels, high costs and a side-effect profile that can become relevant with prolonged use.
The physiological regulation of the GH axis has been well established for decades. Both GH deficiency and GH excess are associated with clinically relevant disorders. This explains why controlled forms of GH stimulation and GH substitution are treated separately in research and clinical practice.
GH secretagogues are particularly relevant in this context because they stimulate the body's own release of growth hormone rather than supplying GH directly. The individual substances differ considerably in receptor profile, half-life, regulatory status and evidence base.
This is where GH secretagogues come in: peptides that prompt the body to release its own growth hormone instead of supplying it from outside. They can be divided into two main classes:
- GHRH analogues (Growth Hormone Releasing Hormone): mimic the hypothalamic releasing hormone
- GHRP (Growth Hormone Releasing Peptides): act via the ghrelin receptor (GHS-R1a)
This article compares frequently discussed representatives of both classes - Sermorelin, Tesamorelin, CJC-1295 and Ipamorelin - and explains why combinations of GHRH and GHRP signals have been studied in research.
For research purposes only
This text serves to contextualise research peptides and clinically studied compounds in the context of the GH axis. It does not constitute medical advice and does not replace consultation with a physician.
GHRH Peptides: Mimicking the Natural Release Signal
GHRH (Growth Hormone Releasing Hormone) is a 44-amino-acid peptide hormone produced in the hypothalamus. It binds to the GHRH receptor (GHRH-R) on somatotropic cells of the pituitary and triggers the synthesis and secretion of growth hormone.
GHRH analogues imitate this natural signalling pathway. The result is a pulsatile GH release that more closely resembles the physiological pattern than exogenous HGH.
Sermorelin: GHRH(1-29)
Sermorelin is the shortest biologically active fragment of natural GHRH. It consists of the first 29 amino acids and retains the essential receptor-binding activity of the native 44-amino-acid peptide.
Properties at a glance:
- Structure: GHRH(1-29)NH2
- Half-life: approximately 10-20 minutes
- Mechanism: Direct activation of the GHRH receptor
- GH release: Pulsatile, physiological
- Negative feedback: Remains intact; somatostatin can continue to regulate GH secretion
Sermorelin was historically approved as a drug in the United States but was later discontinued and has been on the FDA list of discontinued drug products since 2008. For research purposes it remains relevant because it preserves the natural feedback loop of the GH axis, which conceptually distinguishes it from direct HGH administration.
Tesamorelin: GHRH with Improved Stability
Tesamorelin is a modified GHRH analogue in which a trans-3-hexenoic acid group has been attached to the tyrosine residue at position 1. This modification improves stability compared to native GHRH.
Key features:
- FDA approval since 2010 for the reduction of excess visceral fat in HIV-associated lipodystrophy
- Clinical studies showed a significant reduction in visceral adipose tissue, typically in the range of approximately 15 to 20% in published studies
- Further studies have examined effects on metabolic parameters and liver fat
- Preserves the GHRH-based mechanism of pulsatile GH release
Tesamorelin occupies a special position in this comparison because it is not only a research peptide but also a clinically approved drug with randomised, placebo-controlled data on visceral adipose tissue.
CJC-1295: Long-Acting GHRH Analogue
CJC-1295 is a synthetic GHRH analogue with 30 amino acids. In the research context, a distinction is usually made between a DAC variant and shorter-acting modified GHRH analogues:
- CJC-1295 with DAC (Drug Affinity Complex): Binds covalently to albumin in the blood, extending the half-life to 6-8 days
- CJC-1295 without DAC / Mod GRF 1-29: These designations are often equated in the market but should not be used as fully synonymous chemically. They refer to shorter-acting GHRH analogues with several amino acid substitutions for increased stability, with half-lives in the range of approximately 30 minutes
The DAC variant leads to considerably longer exposure, while shorter-acting variants are more commonly discussed for pulsatile protocols. Which form is preferred depends on the respective research design.
GHRP Peptides: The Ghrelin Pathway
Growth Hormone Releasing Peptides act via a different mechanism than GHRH analogues. They bind to the ghrelin receptor (GHS-R1a) - the same receptor activated by ghrelin. This receptor is located both in the pituitary and in the hypothalamus.
Compared to GHRH, it is particularly important that GHRPs can act synergistically. They amplify the GHRH signal and can release GH even when GHRH tone is low.
Ipamorelin: A Selective GHRP
Ipamorelin is considered a selective representative of the Growth Hormone Releasing Peptides. It is a pentapeptide (5 amino acids) that binds to GHS-R1a.
What distinguishes Ipamorelin from other GHRPs:
- In early human studies, no relevant ACTH or cortisol elevation was observed compared to GHRP-2 and GHRP-6
- Prolactin increases were also less pronounced in these studies than with older GHRPs
- Dose-dependent GH release was described
- Appetite stimulation is considered lower compared to GHRP-6
In the literature, Ipamorelin is therefore frequently described as a comparatively selective GHS-R1a agonist.
Highly selective growth hormone releaser that triggers natural GH pulses without raising cortisol or prolactin. Clean GH stimulation with minimal side effects - the most targeted growth hormone peptide available.
GHRP-6 and GHRP-2: The Older Representatives
GHRP-6 was one of the first synthetic GH secretagogues. It produces a marked GH release, but with a broader activity profile:
- GHRP-6: Marked appetite stimulation through GHS-R1a activation, plus increases in cortisol and prolactin observed in studies
- GHRP-2: Potent GH release, but also described with cortisol and prolactin increases
Both peptides remain relevant for mechanistic comparisons, but clearly differ from Ipamorelin in their secondary hormone profile.
A study published in 2026 and available via PMC examined secondary structure, thermal stability and membrane interactions of GH-releasing peptides. The results suggest that membrane interactions may contribute to the biological activity of GHRPs. This is particularly relevant for formulation and model systems.
The Synergy: Why GHRH + GHRP Work Stronger Together
A consistent finding in secretagogue research is that GHRH and GHRP can act synergistically, not merely additively. This means that combined GH release can exceed the individual effect of either component.
The reason lies in the different signalling pathways:
- GHRH activates GHRH-R - cAMP-dependent signalling pathway - GH synthesis and release
- GHRP/Ipamorelin activates GHS-R1a - IP3/PKC signalling pathway - enhanced GH release + suppression of somatostatin
By simultaneously activating both pathways, the somatotropic cell is stimulated via multiple signalling cascades, while the inhibitory signal somatostatin can be attenuated at the same time.
CJC-1295/Ipamorelin: A frequently discussed combination
The combination of a shorter-acting GHRH analogue such as CJC-1295 without DAC or Mod-GRF variants and Ipamorelin is often discussed together in the research community. The rationale is mechanistically coherent: a GHRH signal on one side, a GHRP stimulus on the other.
2-in-1 growth hormone blend: CJC-1295 + Ipamorelin in one vial. Stimulates natural GH release through two different pathways for amplified, more physiological growth hormone pulses. The gold standard GH research combination.
Direct Comparison: GHRH vs GHRP at a Glance
| Property | GHRH Analogues (Sermorelin, Tesamorelin, CJC-1295) | GHRP (Ipamorelin) |
|---|---|---|
| Receptor | GHRH-R | GHS-R1a (Ghrelin receptor) |
| Signalling pathway | cAMP/PKA | IP3/PKC |
| Site of action | Pituitary (direct) | Pituitary + Hypothalamus |
| Somatostatin inhibition | No | Yes (indirect) |
| GH release alone | Moderate | Moderate |
| GH release combined | Synergistically enhanced | Synergistically enhanced |
| Pulsatility | Physiological | Physiological |
| Cortisol influence | No direct effect expected | Low with Ipamorelin, elevated described with GHRP-6/2 |
| Prolactin influence | No direct effect expected | Low with Ipamorelin, elevated described with GHRP-2/6 |
| Half-life | 10 min (Sermorelin) to 8 days (CJC-1295 DAC) | approx. 2 hours |
Research context
Combinations of GHRH and GHRP analogues show a stronger GH response in experimental models and acute human studies than either substance alone. Clinical data on long-term effects of such combinations remain limited.
Where Does IGF-LR3 Fit In?
All peptides discussed so far act upstream - they stimulate GH release from the pituitary. The released GH then acts on the liver and other tissues, where it stimulates the production of IGF-1 (Insulin-like Growth Factor 1). IGF-1 mediates a large part of the anabolic and regenerative effects of growth hormone.
IGF-1 LR3 (Long R3 IGF-1) is a modified IGF-1 analogue with:
- Substitution of glutamic acid at position 3 with arginine (R3 substitution)
- N-terminal extension of 13 amino acids
- Markedly reduced binding to IGF-binding proteins (IGFBPs), which increases bioavailability
- Regarding half-life, values in the range of 20 to 30 hours are frequently cited for IGF-1 LR3; however, robust human PK data on this are limited. For comparison, the terminal half-life of recombinant human IGF-1 in human studies is on the order of approximately 20 hours.
IGF-LR3 bypasses the entire GH axis and acts directly at the IGF-1 receptor. This makes it a fundamentally different research tool: it does not ask whether the pituitary is functioning but directly examines the downstream effects of the GH/IGF-1 axis.
| Comparison point | GH Secretagogues (GHRH/GHRP) | IGF-1 LR3 |
|---|---|---|
| Site of action | Hypothalamus/Pituitary | Peripheral tissues directly |
| Feedback regulation | Preserved | Bypassed |
| GH increase | Yes | No; suppression of endogenous GH secretion is derived primarily from preclinical data |
| Insulin sensitivity | Neutral to slightly reduced | May enhance insulin action |
| Research focus | GH deficiency, ageing, body composition | Muscle biology, cell proliferation |
Frequently Asked Questions
The substances described here have different regulatory status depending on the active ingredient. This article is for informational purposes only and does not replace medical advice. It is not to be understood as a recommendation for use in humans.